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cal periadventitial application up to 1.5-fold. Both sPLLs sig-
nificantly increased liposome-mediated GT. Poly- L -lysine L18 
was superior to LMW-L since it enabled maximal GT at a 10-
fold lower concentration. Thus, sPLLs may serve as enhanc-
ers for GT applications in SMCs in vitro and in vivo using local 
delivery.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Conventional drug therapy has limitations that can be 
overcome using gene therapy  [1] . The advantages of gene 
therapy are the long-lasting effects, tolerance of gene con-
structs, the possibility to direct the expression of the ther-
apeutic gene to certain cell types and low unwanted side 
effects, in particular using local delivery  [2] . Gene thera-
py represents, among other applications, a promising al-
ternative for treatment of vascular disease, e.g., the pre-
vention of restenosis following angioplasty. Neointima 
formation after balloon dilatation is caused mainly by 
proliferation of smooth muscle cells (SMCs) and matrix 
formation  [3] . Thus, inhibition of SMC proliferation also 
has a suppressive effect on restenosis  [4, 5] . The arterial 
wall is accessible by drug delivery catheters that facilitate 
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 Abstract 
 The potential of two small poly- L -lysines (sPLLs), low molec-
ular weight sPLL (LMW-L) containing 7–30 lysine residues 
and L18 with 18 lysine repeats, to enhance the efficiency of 
liposome-mediated gene transfer (GT) with cationic lipid 
DOCSPER [1,3-dioleoyloxy-2-(N 5 -carbamoyl-spermine)-pro-
pane] in vascular smooth muscle cells (SMCs) was investi-
gated. Dynamic light scattering was used for determination 
of particle size. Confocal microscopy was applied for colocal-
ization studies of sPLLs and plasmid DNA inside cells. GT was 
performed in proliferating and quiescent primary porcine 
SMCs in vitro and in vivo in porcine femoral arteries. At low 
ionic strength, sPLLs formed small complexes with DNA (50–
100 nm). At high ionic strength, large complexes ( 1 1   m) 
were observed without any significant differences in particle 
size between lipoplexes (DOCSPER/DNA) and lipopolyplex-
es (DOCSPER/sPLL/DNA). Both sPLLs were colocalized with 
DNA inside cells 24 h after transfection, protecting DNA 
against degradation. DOCSPER/sPLL/DNA formulations en-
hanced GT in vitro up to 5-fold, in a porcine model using lo-
 Received: December 1, 2006 
 Accepted after revision: February 7, 2007 
 Published online: March 30, 2007 
 
 Prof. Dr. Sigrid Nikol 
 Department of Cardiology and Angiology 
 Medizinische Klinik und Poliklinik C, University of Münster 
 Albert-Schweitzer-Strasse 33, DE–48129 Münster (Germany) 
 Tel. +49 251 834 8501, Fax +49 251 834 5101, E-Mail nikol@uni-muenster.de 
 © 2007 S. Karger AG, Basel 
 1018–1172/07/0444–0273$23.50/0 
 Accessible online at: 
 www.karger.com/jvr 
 Golda  /Pelisek  /Klocke  /Engelmann  /
Rolland  /Mekkaoui  /Nikol  
 J Vasc Res 2007;44:273–282 274
the local deposition of active agents  [6] . It has been shown 
that perivascular events significantly affect neointima: 
adventitial irritation results in focal intimal thickening 
and markers applied to the adventitia can be visualized 
in the intima  [7, 8] . Therefore, vascular SMCs may be a 
suitable target using adventitial deposition of gene thera-
py vectors  [3, 9] . 
 Viral and non-viral vector systems have been devel-
oped for gene transfer (GT). Viral vectors are powerful 
vehicles for GT into somatic cells  [10] . Adenoviral vectors 
have been widely used in vascular GT. However, such 
gene carriers based on viral vectors are highly immuno-
genic, relatively difficult to handle compared with plas-
mids and require enhanced biosafety levels. In contrast, 
non-viral vectors are cost-efficient, easy to handle and 
hardly induce any immune response. Furthermore, no 
specific infrastructure is necessary. Non-viral vector sys-
tems are usually composed of either ‘naked’ DNA or 
DNA complexed with amphipathic complexing agents to 
achieve higher transfer efficiencies  [11] . 
 During the past years, liposome-mediated, non-viral 
GT has been considerably improved by the introduction 
of new cationic lipid formulations  [12] . Cationic lipids 
condense DNA through ionic interactions, thereby form-
ing lipoplexes  [13] . Despite such improvements, non-vi-
ral GT, in particular transfections of stationary or low 
proliferating cells, remained rather inefficient  [13] . Nev-
ertheless, optimization of GT conditions using cationic 
lipids led to significantly improved transfection rates in 
cultures of proliferating or stationary primary vascular 
cells as well as in vivo in a porcine restenosis model  [14] . 
Yet, GT efficiency still needs further improvement to 
achieve high levels of gene expression for clinical use. 
One of the limitations for sufficient levels of gene expres-
sion is the relatively inefficient release of DNA from en-
dosomes into the cytoplasm and the limited protection of 
DNA against cytoplasmic nucleases allowing for high 
amounts of intact DNA to enter the nucleus. Promising 
DNA-condensing agents are cationic polymers like poly-
lysines, polyarginines, spermine, spermidine, dendrimers 
and polyethylenimine  [15] . These polymers are believed 
to still adhere to DNA after endosomal release, thus al-
lowing for enhanced protection of the DNA against cyto-
plasmic nucleases. Poly- L -lysines were already used to 
condense DNA into a virus-like structure  [16] . However, 
they alone are rather inefficient in promoting GT. Fur-
thermore, their toxicity significantly increases with mo-
lecular weight  [17] . 
 Promising alternatives are lipopolyplexes, i.e. the 
combination of cationic lipids and cationic polymers, 
e.g., poly- L -lysine. Plasmid DNA complexed with poly- L -
lysine of 23.8 kDa (163 lysine residues) and liposomes al-
lowed for significantly improved GT  [18] . However, short 
poly- L -lysines (sPLLs) of 13–18 lysine residues are char-
acterized by already sufficient DNA binding capacity but 
low toxicity  [19] . Therefore, we investigated the capabil-
ity of two sPLLs – L18 with 18  L -lysine residues and low 
molecular weight poly- L -lysine (LMW-L) which is a 
mixture of poly- L -lysines containing 7–30  L -lysine resi-
dues – in enhancing liposome-mediated transfection. 
Furthermore, GT experiments were performed in prima-
ry porcine SMCs representing more suitable cell culture 
models better mimicking the in vivo conditions. 
 Materials and Methods 
 DNA Plasmid, Liposomes and Adjuvants 
 A   -galactosidase reporter gene vector pCMV  (7.2 kb, cyto-
megalovirus-driven galactosidase gene; Clontech, Heidelberg, 
Germany) and the cationic lipid DOCSPER [1,3-dioleoyloxy-2-
(N 5 -carbamoyl-spermine)-propane]  [20] were used for transfec-
tions. LMW-L (1–4 kDa) was purchased at Sigma-Aldrich (Mu-
nich, Germany) and L18 (2.6 kDa) was synthesized to a purity 
 1 95% by Dr. Arnold (Gene Center, Munich, Germany). Both are 
referred to as sPLLs. 
 Complex Formation 
 Lipopolexes or polyplexes were prepared as follows: first, plas-
mid DNA (pCMV  ) and DOCSPER or poly- L -lysine were diluted 
in separate tubes using either OptiMEM (Gibco, Eggenstein, Ger-
many; high ionic strength solution) or deionised water (low ionic 
strength solution). Cationic lipid or polymer dilution was then 
added to the DNA tube at different ratios (DOCSPER/DNA 1/1–
12/1; sPLL/DNA 1/1–50/1; w/w), mixed and incubated at room 
temperature for 30–40 min to allow for complex formation. In the 
case of lipopolyplexes, DNA was first pre-complexed with sPLLs 
by adding the polymer at different ratios directly into the tube 
with plasmid DNA, mixed and incubated for 5–15 min prior to 
the addition of the diluted DOCSPER again at various ratios and 
incubated at room temperature for additional 30–40 min. 
 Particle Size Measurement 
 Particle size was determined using dynamic light scattering 
with Zetasizer 3000HS (Malvern Instruments, Malvern, UK) us-
ing 10 subruns for each measurement in a 400-  l complex solu-
tion volume. Complexes were prepared as for GT and diluted ei-
ther in low or high ionic strength solution (deionized water or 
OptiMEM). Formulations were analysed by measuring particle 
size in 10-min intervals for up to 60 min following the complex 
formation. 
 Resistance against DNase I Degradation 
 Lipoplexes and lipopolyplexes were prepared in 400   l Op-
tiMEM as described above using 2.5   g/ml of plasmid DNA. Fol-
lowing complex formation, 400   l DNase I solution, i.e. 60 U/ml 
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DNase I (Promega, Munich, Germany) and 1 m M MgCl 2  in Hanks’ 
balanced salt medium, was added and complexes were incubated 
at 37  °  C for 0, 15, 30, 45 and 60 min. The enzyme reaction was 
terminated by addition of stop solution (Promega) and incubation 
at 65  °  C for 10 min. Then, sodium dodecyl sulphate was added to 
a final concentration of 10% to release DNA from the condensing 
reagents, and 20   l of samples were loaded on a 0.8% agarose gel. 
The integrity of DNA in each formulation was compared with 
untreated DNA as a control. 
 Cell Cultures 
 Primary porcine SMCs were isolated from explants of porcine 
aorta  [4, 21] . The outgrowing SMCs were tested by immunohisto-
chemistry for   -smooth muscle actin expression  [21] . The cells 
were cultured in medium (Ham’s F-12/Waymouth 1/1; Gibco) 
containing 10% fetal calf serum, 4 m M glutamine, 100 U penicil-
lin, 100   g/ml streptomycin and 2.5 mg/ml amphotericin B (Bio-
chrom, Berlin, Germany) as previously described  [4] . 
 Transfection in vitro 
 The cells were seeded into 12- or 96-well plates 24 h prior to 
transfection. For the inhibition of SMC proliferation, cells were 
incubated with 300   g/ml heparin (Braun, Melsungen, Germany) 
for further 24 h before transfection and following each medium 
change  [14] . GT by using the cationic lipid DOCSPER was per-
formed as described previously  [14, 22] . Four hours following 
complex addition, transfection medium was replaced with fresh 
growth medium, and after an additional 2 days, GT efficiency was 
determined by measuring   -galactosidase activity. 
 Transfection in vivo 
 Optimal transfer conditions found in cell cultures were used 
for local gene delivery in a pig model using needle injection cath-
eter as described previously  [4, 12, 21, 23, 24] . Briefly, the arte-
rial access was gained through carotid artery. X-ray contrast an-
giography was performed to guide the insertion and to make sure 
that the needle injection catheter (Bavaria Medicine Technology, 
Oberpfaffenhofen, Germany) is in the desired position at the site 
of the femoral artery. When in position, the fine needles were 
extended to penetrate the arterial wall into the perivascular tis-
sue, and the transfection medium was deposited by a special in-
jection pump place at the distal end of the catheter. This proce-
dure ensures deposition of transfection solution within a region 
of about 2–3 cm diameter around the vessel into the adventitial 
tissue. After delivery of transfection medium, needles were re-
tracted and the catheter was removed. All animal procedures 
were approved by the Animal Care and Use Review Committee 
of the University of Marseille according to French guidelines. 
The investigation conforms to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of 
Health (NIH publication No. 85-23, revised 1996) .  Study animals 
were Pietrain pigs (average weight 35 kg at the initial procedure; 
n = 6). In each femoral artery transfection was performed with 
30   g plasmid DNA complexed with 300   g DOCSPER or pre-
complexed with poly- L -lysine for 5–15 min and then mixed with 
DOCSPER in 2 ml OptiMEM (Gibco). Animals were sacrificed 
3 weeks following transfection, and the 4-cm-long specimens of 
each femoral artery were surgically dissected in the way that the 
transfection site was located in the middle of the specimen. The 
explanted artery was then subdivided into 8 equal segments and 
marked from distal to proximal as S1 to S8. Samples 1, 3, 5 and 7 
of each artery were snap-frozen in fluid nitrogen and used for 
DNA and expression analysis. Segments 2, 4, 6 and 8 were used 
for histological analyses (data not shown). Persons performing 
transfection in vivo, the extraction of specimens and the expres-
sion analysis were unaware of the deposition of the transfection 
vectors.   -galactosidase activity was measured as previously de-
scribed  [23] . 
 Fluorescent Staining, Flow Cytometry and Confocal 
Microscopy 
 For flow cytometric analysis, proliferating SMCs were seeded 
into 12-well plates and cultivated as previously described  [9, 14, 
22] . Transfection with Cy5-labelled (excitation at 650 nm, emis-
sion at 670 nm) plasmid DNA (Mirus Bio Corporation, Madison, 
Wisc., USA), unlabelled sPLLs and DOCSPER was done as de-
scribed above. Four hours following gene delivery, the transfec-
tion medium was removed, cells were washed with phosphate-
buffered saline (PBS) and treated with 500   g/ml heparin for 
30 min at 37  °  C to remove extracellular bound complexes. Subse-
quently, cells were trypsinised and measurement was performed 
with FACSCalibur (Becton Dickinson, Biosciences, San Jose, 
 Calif., USA). 
 For colocalisation of sPLLs and plasmid DNA inside the cell, 
frequency resonance energy transfer (FRET), confocal micros-
copy and two assays from Molecular Probes (Madison, Wisc., 
USA) were used: Alexa Fluor 488 (494 nm/519 nm) protein 
 labelling kit for labelling of sPLLs and Label IT TM-Rhodamine 
(546 nm/576 nm) labelling kit for DNA. Stationary SMCs were 
seeded on Lab-Tek 8-well chambered cover glasses (Nalge Nunc 
International, Naperville, Ill., USA) 24 h prior to transfection. 
Four and 24 h following transfection, cells were washed with PBS, 
fixed with 4% paraformaldehyde, and nuclei were stained with 
DAPI fluorochrome (1   g/ml final concentration in PBS) for 
5 min. DAPI staining solution was than replaced by PBS and sam-
ples were analysed using a confocal laser scanning microscope 
(LSM 510, Zeiss, Jena, Germany). 
 Analysis of Toxicity 
 For the determination of toxicity, the CellTiter 96 Aqueous 
One Solution Cell Proliferation Assay (Promega) was used. Two 
days following incubation with SPLL-enriched cell culture me-
dium in 96-well plates, cells were washed with PBS, 100   l fresh 
growth medium containing 20   l of tetrazolium compound 
(MTS) was added (final concentration: 33   g/ml MTS, 25   g/ml 
phenazine methosulphate), and the 96-well plate was incubated 
at 37  °  C/5% CO 2  for an additional 2 h. The tetrazolium compound 
of the assay is bioreduced by cells into a coloured formazan prod-
uct that is soluble in tissue culture medium and corresponds to 
the amount of metabolically active cells, and the optical absor-
bance is directly proportional to the number of living cells in the 
culture. The colour development was determined using an ELISA 
reader (Titertek Multiscan MCC 340, Eflab, Helsinki, Finland) at 
490 nm, with a reference at 690 nm. The cellular toxicity of cells 
treated with the raising concentration of sPLLs was expressed in 
percent of non-treated cells. As a positive control (100%), samples 
without sPLLs treatment were used (0   g/ml sPLL). The negative 
control (0%) presented samples without cells containing growth 
medium and tetrazolium compound. 
 Golda  /Pelisek  /Klocke  /Engelmann  /
Rolland  /Mekkaoui  /Nikol  
 J Vasc Res 2007;44:273–282 276
 Statistical Analysis 
 Results are means  8 standard deviation (SD) of a minimum 
of 3 experiments for each condition. One-way ANOVA was used 
for comparison among groups (SPSS Inc., Chicago, Ill., USA). Sta-
tistical significance was defined as p  ! 0.05. 
 Results 
 Complex Formation and Particle Size Measurement 
 First, the sizes of sPLL/DNA particles forming at low 
and high ionic strength were measured ( table 1 ). In solu-
tions of low ionic strength and at sPLL/DNA ratios  1 1/1, 
both L18 and LMW-L formed small complexes  ! 100 nm 
in size. These formulations tended to form more tight 
complexes with decreasing size when the sPLL/DNA 
weight/weight (w/w) ratio was further increased. In gen-
eral, the particle sizes tended to decrease with increasing 
sPLL/DNA ratios in low ionic strength solution. At high 
ionic strength (OptiMEM), both L18 and LMW-L, inde-
pendent of the weight ratio used, formed particles with 
DNA  1 1   m: up to 2,206  8 976 nm for L18/DNA and 
up to 1,789  8 348 nm for LMW-L/DNA. However, small 
complexes ranging from 190  8 46 to 323  8 119 nm were 
also observed ( table 1 ). To determine the time-depen-
dent formation and sizes of different lipopolyplex for-
mulations, a L18/DNA ratio of 5/1 and a LMW-L/DNA 
ratio of 50/1 were selected, and the particle sizes were 
compared with those of lipoplexes of DOCSPER ( ta-
ble 2 ). Again, two subpopulations, one of large particles 
with sizes of up to 2,180  8 409   m and one of small par-
ticles between 109  8 14 and 386  8 18 nm, were identi-
fied. There were no significant differences in size be-
tween the lipoplexes and lipopolyplexes. All types of ag-
gregates already formed during the first 10 min following 
mixing of the components. For up to 1 h, none of the 
complexes displayed significant changes in particle size 
( table 2 ). 
 Resistance against DNase I Degradation 
 To analyse the ability of sPLLs to protect DNA from 
degradation, complexes of sPLLs with plasmid DNA were 
Solution sPLL sPLL/DNA ratio
1/1 5/1 10/1 50/1
Water L18 108829 62818 58817 43813
LMW-L 295813 75817 64821 52814
OptiMEM L18 2,2068976* 2,0678398* 1,6728242* 1,0778443*
263871** 242865** 233833** 219887**
LMW-L 1,1348387* 1,4568421* 1,5978266* 1,6898348*
3238119** 292887** 2678126** 190846**
Large- (*) and small-sized particles (**) of these complexes were observed.
 
 
 Table 2. Particle size (nm) of lipoplexes of DOCSPER and lipopolyplexes of DOCSPER/sPLLs 
Weight ratio 10 min 20 min 30 min 40 min 60 min
DOCSPER/DNA (6/1) 2,1808409* 1,8508340 1,7308321 1,8928172 2,2998454
181833** 211839 265814 238841 221841
DOCSPER/LMW-L/DNA (6/50/1) 1,2898133 1,5188106 1,9378178 1,6068134 1,367894
143814 221818 386818 264838 187847
DOCSPER/L18/DNA (6/10/1) 1,8978456 1,6708377 1,5628324 1,6848382 1,0518272
178833 162834 158824 154837 109814
Two subpopulations were observed: large (*) and small sized (**).
 
 Table 1. Particle size (nm) of sPLL/
DNA complexes 30 min following 
complexation 
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treated with DNase I ( fig. 1 ). Both types of sPLLs pro-
tected plasmid DNA against nuclease degradation for up 
to 45 min ( fig. 1 a). In complexes with L18, the DNA dis-
played a slightly higher resistance against DNase I than 
in those with LMW-L. However, after 60 min of incuba-
tion of sPLL/DNA polyplexes with DNase I, plasmid 
DNA was almost completely degraded ( fig. 1 a). In con-
trast, lipopolyplexes of sPLLs and DOCSPER were stable 
against degradation for at least 60 min following DNase 
I addition ( fig. 1 b). Uncomplexed DNA was digested 
within the first minutes following DNase I addition (data 
not shown). 
 Cellular Uptake and Intracellular Colocalization 
 Plasmid DNA was fluorescently labelled with Cy5 and 
used to examine the internalisation of transfection com-
plexes into SMCs. Flow cytometric analysis of cellular up-
take following addition of lipoplexes with DOCSPER and 
lipopolyplexes containing DOCSPER and L18 or LMW-L 
was carried out after 2, 4 and 24 h ( table 3 ). Results dem-
onstrated no difference in cellular uptake independent of 
the formulation used; only the velocity of the internalisa-
tion varied. Twenty-four hours following complex addi-
tion, all cells ( 1 98%) were positive for the transfected 
DNA. Lipoplexes of DOCSPER and DNA seemed to be in-
ternalised faster than lipopolyplexes, with more than 50% 
positive cells already 2 h following transfection. For lipo-
polyplexes, no significant difference in the velocity of in-
ternalisation was observed between complexes with L18 or 
LMW-L. In contrast, the uptake of naked DNA was very 
low with up to 4% after 4 h. At 24 h, no significant amount 
of naked DNA was detected inside the cells ( table 3 ). 
 Intracellular colocalisation of DNA and sPLLs after 4 
and 24 h was analysed by the detection of FRET using 
confocal microscopy ( fig. 2 ). Following the addition of 
double-labelled L18/DNA or LMW-L/DNA formulations 
to SMCs, the excitation of tetramethyl (TM)-rhodamine-
labelled DNA caused the emission of AlexaFluor (sPLL 
labelling) in all cases indicating the colocalisation of 
DNA and sPLLs up to 24 h following complex delivery. 
No differences in colocalisation results were observed be-
tween L18/DNA or LMW-L/DNA formulations used. 
LMW-La
b
L18
15 min 30 min 45 min 60 min
LMW-L L18 LMW-L L18 LMW-L L18
LMW-L L18DOCLMW-L L18DOC LMW-L L18DOC LMW-L L18DOC
15 min 30 min 45 min 60 min
 Fig. 1. Resistance of DNA against DNase I 
degradation in complexes with sPLLs (L18 
or LMW-L) ( a ) or sPLLs and DOCSPER 
(lipopolyplexes) in comparison with DNA 
in lipoplexes of DOCSPER ( b ). Polyplexes 
of sPLL/DNA or lipopolyplexes of DOC-
SPER/sPLL/DNA were formed as de-
scribed in Materials and Methods. DOC = 
DOCSPER/DNA formulation. 
2 h 4 h 24 h
Naked DNA 2.6580.86 4.2581.78 0.2580.42
DOCSPER/DNA 58.6081.13 79.9085.23 98.1582.05
DOCSPER/L18/DNA 30.6581.06 61.7586.86 98.5080.99
DOCSPER/LMW-L/DNA 30.2583.04 63.8589.40 98.5080.85
The same conditions for complex formation were used as described in table 2. Uptake 
efficiency is indicated as percentage of all cells. For detecting internalised complexes, 
cells were treated with heparin prior to measurement (see also Materials and Meth-
ods).
 
 Table 3. Internalisation of lipoplexes of 
DNA with DOCSPER and lipopolyplexes 
of DNA with L18 or LMW-L into SMCs
at different time points using Cy5 
 fluorescently labelled plasmid DNA
and flow cytometry 
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 Toxicity of sPLLs on SMCs 
 To investigate the toxicity of sPLLs on SMCs, cells were 
incubated with increasing concentrations of L18 and 
LMW-L for up to 500   g/ml. After 24 h of incubation and 
up to the concentration of 100   g/ml sPLLs, no toxic ef-
fects on SMCs were observed for both LMW-L and sPLL 
( fig. 3 ). This concentration was significantly higher than 
the concentration used in the transfection experiments. 
The synthetic poly- L -lysine L18 seemed to be less toxic 
than LMW-L; however, the differences in cell viability 
were not statistically significant. 
Without FRET
L18
LMW-L
With FRET 
L18 
L18 L18 
LMW-L 
LMW-L LMW-L 
 Fig. 2. Intracellular colocalisation of DNA 
and sPLLs by FRET using confocal mi-
croscopy in stationary SMCs 4 h ( a ) and 
24 h ( b ) following GT with lipopolypexes 
of DOCSPER/sPLL/DNA. DNA was la-
belled with TM-rhodamine and sPLLs 
with AlexaFluor 488 to enable FRET visu-
alisation. Cell nuclei were stained with 
DAPI. Left panels: TM-rhodamine fluo-
rescence emission after specific excitation 
of TM-rhodamine (emission at 546 nm, 
excitation at 576 nm; without FRET). Right 
panels: TM-rhodamine emission after ex-
citation of AlexaFluor 488 (emission at 494 
nm, excitation at 519 nm; with FRET). 
 a 
 b 
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 Transfection in vitro 
 To analyse the effect of sPLLs as components of lipo-
polyplexes on GT efficiency, various amounts of sPLLs 
were used for transfection of proliferating and quiescent 
SMCs. As a control, GT with lipoplexes of DOCSPER 
without sPLLs was performed. The DOCSPER/DNA ratio 
used for proliferating cells was 6/1 and for stationary 
SMCs 10/1  [14, 22] . In proliferating SMCs, lipopolyplexes 
containing L18 displayed an up to 2-fold higher transfec-
tion efficiency than the corresponding lipoplexes. The 
maximal GT efficiency was achieved using 5–10   g of L18 
and 1   g plasmid DNA per 100,000 cells ( fig. 4 a). Pre-in-
cubation of DNA with LMW-L increased GT efficiency 
for up to 2.5-fold in comparison with the transfer effi-
ciency of lipoplexes alone. Maximal GT was achieved us-
ing 50–100   g LMW-L and 1   g plasmid DNA per 100,000 
cells. Thus, to achieve maximal GT efficiency of lipopoly-
plexes with LMW-L, a 10-fold higher sPLL concentration 
was necessary compared with lipopolyplexes with L18. In 
stationary SMCs, L18 increased the GT efficiency up to 
6-fold at L18/DNA weight ratios of 5/1 and 10/1. At high-
er ratios up to 100/1 (L18/DNA), the transfer efficiency 
remained almost constant. Lipopolyplexes with LMW-L 
displayed maximal GT at an LMW-L/DNA ratio of 50/1 
( fig. 4 b). In stationary SMCs, L18 and LMW-L lipopoly-
plexes exhibited comparable maximal GT efficiencies. 
 Transfection in vivo 
 The effects of lipopolyplexes on transfection were also 
analysed in vivo in a porcine model. Since a significant 
lower concentration of L18 than of LMW-L was required 
in vitro for maximal GT efficiency (5–10   g L18 vs. 50   g 
LMW-L per 1   g plasmid DNA and 100,000 cells), L18 
was chosen as sPLL for in vivo  experiments. The ratio of 
DOCSPER/DNA lipoplexes used was 10/1 (w/w; optimal 
ratio found in GT experiments with stationary primary 
porcine SMCs in vitro)  [14, 22] . For lipopolyplexes, the 
ratio of DOCSPER/L18/DNA was 10/10/1 (w/w/w). Three 
weeks following local application of L18 lipopolyplexes, 
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plexes used for gene transfer of a   -galactosidase-encoding DNA 
plasmid in proliferating ( a ) or quiescent ( b ) porcine SMCs.  * Sig-
nificant enhancement of   -galactosidase activity of lipopolyplex-
es comprising sPLL in comparison with lipoplexes of DOCSPER 
(0 = without sPLL). 
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up to 1.5-fold higher   -galactosidase activities were ob-
served in protein extracts from arterial segments as com-
pared with the application of lipoplexes of DNA and 
DOCSPER ( fig. 5 ). 
 Discussion 
 This study was designed to reveal a possible advantage 
of the use of sPLL L18 (2.6 kDa, 18 lysine residues) or 
LMW-L (1–4 kDa, 7–30 lysine residues) in liposomal gene 
delivery in cultures of primary porcine SMCs in vitro and 
in vivo in a porcine femoral artery using local delivery. In 
addition to the analysis of GT efficiencies, the influences 
of the sPLLs L18 and LMW-L on liposome/DNA complex 
formation, stability, resistance against degradation by 
nucleases, uptake into the cells and visualisation of the 
complexes inside the cells were tested. 
 Biophysical properties such as the size of DNA com-
plexes play an important role in GT efficiency  [25, 26] . 
Therefore, the sPLL/DNA complexes were first charac-
terised with regard to particle size. Both L18 and LMW-L 
formed small complexes with DNA at low ionic strength. 
However, at the sPLL/DNA ratio of 1/1, complexes with 
L18 were significantly smaller than those with LMW-L. 
At ratios of 5/1 and higher, the sizes of both types of com-
plexes were similar. These results can be explained by the 
fact that LMW-L contains a mix of lysine chains of dif-
ferent lengths (7–30 lysine residues). Poly- L -lysines with 
13 or less lysine repeats bind DNA weakly and produce 
large DNA condensates  [19] . Thus, LMW-L contains low-
er amounts of poly- L -lysines with high DNA binding ca-
pacity at the same concentration as L18. Therefore, high-
er amounts of LMW-L are necessary to reach the same 
degree of DNA condensation. At high ionic strength, ag-
gregates were observed for both sPLLs independent of the 
sPLL/DNA ratio. The appearance of two subpopulations 
coincided with the measured high polydispersity of com-
plexes. 
 Similar to the corresponding lipoplexes, lipopolyplex-
es of sPLLs, DNA and DOCSPER displayed particle sizes 
 1 1   m already 10 min following mixing of components 
at high ionic strength. No significant differences in par-
ticle size or complex-forming kinetics were observed be-
tween the lipopolyplexes with L18 or LMW-L and lipo-
plexes of DOCSPER. Consequently, the high ionic 
strength solution used for transfection should not signif-
icantly contribute to differences in transfer efficiency ob-
served for the various formulations. 
 The uptake of GT particles into cells is another impor-
tant factor influencing transfection efficiency  [27] and 
was therefore comparatively investigated for lipopoly-
plexes containing sPLLs and DOCSPER and the lipoplex 
with DOCSPER. The experiments revealed that DOC-
SPER/DNA lipoplexes were internalised faster than lipo-
polyplexes. However, the amount of complexes finally in-
ternalised after 24 h did not differ between lipoplexes and 
lipopolyplexes, suggesting that the enhanced GT effi-
ciency found for lipopolyplexes was not due to an en-
hanced uptake of these formulations into the cells. These 
data confirm the presumption that the cellular uptake of 
the DNA complexes alone does not give any evidence 
about the efficiency of GT. In addition to the successful 
internalisation, endosomal release, protection against 
degradation inside the cell and effective translocation in 
the nucleus are additional necessary properties of an ide-
al DNA carrier to succeed in GT  [22, 25–27] . In contrast 
to the internalisation of lipoplexes, polyplexes or lipo-
polyplexes, the uptake of naked DNA was very low, and 
24 h following treatment, no significant DNA inside the 
cells was detectable. This again confirms the fast degra-
dation of unprotected DNA outside and also inside the 
cells, thus showing that naked DNA is not suitable for 
transfection. 
 Following endosomal release of DNA into the cyto-
plasm, its degradation by nucleases may significantly di-
minish transfection efficiency. In previous experiments, 
it was demonstrated that complexation of plasmid DNA 
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 Fig. 5.   -galactosidase activity in porcine iliac arteries in vivo 3 
weeks following gene transfer using DOCSPER/DNA lipoplexes 
(left) versus DOCSPER/L18/DNA lipopolyplexes (right). S1–S7 = 
Individual segments of the explanted femoral artery analysed 
separately for   -galactosidase activity; K1 = non-transfected con-
trol tissue.  * p  ! 0.05. 
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with poly- L -lysine of a molecular weight of 25 kDa effi-
ciently protects DNA from DNase I digestion  [28] . Our 
results demonstrated that polyplexes of L18/DNA dis-
played a slightly higher resistance against DNase I than 
LMW-L/DNA aggregates. This result can be again ex-
plained by a better complexation of DNA by L18 com-
pared with LMW-L due to the defined length of L18 in 
contrast to LMW-L. However, the slightly lower capabil-
ity of LMW-L to protect DNA from DNase I degradation 
did not affect the stability of DNA in the corresponding 
lipopolyplexes in comparison with lipopolyplexes con-
taining L18 and lipoplexes containing only DOCSPER, 
suggesting that the latter is the component predominant-
ly affecting the stability of DNA in lipopolyplexes. 
 Using the FRET technique which enables detection of 
colocalisation of two molecules inside the cell demon-
strated that up to 24 h following GT, sPLLs were still 
bound to DNA, suggesting that DNA is protected from 
degradation by cytoplasmic nucleases after endosomal 
release. Consequently, this would enhance the probabil-
ity for DNA to reach the nucleus and to become expressed 
and may therefore be the key mechanism responsible for 
the higher transfection rates of lipopolyplexes in com-
parison with lipoplexes. 
 Additionally or alternatively, the higher GT efficiency 
achieved by lipopolyplexes with sPLLs versus lipoplexes 
may be due to a higher degree of toxicity. Increased toxic-
ity often contributes to enhanced transfection efficacy 
 [22] . However, investigation of cytotoxicity of the formu-
lations did not reveal any significant decrease in cell vi-
ability for up to 100   g/ml, which was far beyond our 
working concentration of sPLLs. In previous studies, 
poly- L -lysine with a molecular weight of 25 kDa was 
found to improve GT in a number of cell lines  in vitro  [18, 
29] . However, high molecular weight poly- L -lysine is sig-
nificantly more toxic than the low molecular weight 
forms which are almost non-toxic. The concentrations of 
poly- L -lysine used in our experiments had no effect on 
cell proliferation or metabolic activity. 
 Using lipopolyplexes of sPLLs and DOCSPER under 
optimised GT conditions, sPLLs enhanced transfection 
rates not only in proliferating but also in stationary pri-
mary SMCs and improved GT up to 5-fold. The enhance-
ment of GT efficiency in stationary or low proliferating 
cells is particularly important since the proliferation rates 
in our restenosis in vivo model systems are rather low and 
correspond well with the proliferation rates found in sta-
tionary cell cultures established in our previous studies 
by using heparin for growth inhibition  [14] . No signifi-
cant differences in GT efficiency were observed indepen-
dently of the sPLLs used for lipopolyplex transfection. 
However, for lipopolyplexes with L18 in comparison with 
LMW-L, an about 10-fold lower concentration was al-
ready sufficient to achieve maximal GT effect. These dis-
crepancies can be explained by the fact that LMW-L is a 
mixture of poly- L -lysines varying in chain length, which 
display different DNA binding affinities. 
 Li and Huang  [30] showed that cationic lipid-prot-
amine-DNA complexes were highly efficient in in vivo 
GT in a mouse model. However, so far, there was no evi-
dence for an effect of poly- L -lysine pre-condensation on 
liposomal transfection in vivo. In the present paper, a 
supporting effect of sPLLs on transfection in vivo is dem-
onstrated for the first time using a porcine experimental 
model. L18 was chosen for these experiments since its de-
fined length presumably enables the application of a sig-
nificantly lower concentration for maximal effect as it 
can be supposed for LMW-L. An up to 1.5-fold higher GT 
efficiency was observed for DOCSPER/L18/DNA lipo-
polyplexes compared with DOCSPER/DNA lipoplexes. 
 In summary, both low molecular weight poly- L -ly-
sines, LMW-L and L18, significantly increased transfec-
tion efficiency measured by the activity of a reporter gene 
product. Biophysical properties and cellular uptake of 
DOCSPER lipoplexes did not significantly differ from 
the properties and internalisation of lipopolyplexes con-
taining DOCSPER and sPLLs. Therefore, we conclude 
that the enhancement of GT by sPLLs is mainly due to the 
enhanced protection of transgene DNA by sPLLs against 
nuclease degradation in the cytoplasm and to a potential 
synergistic effect of sPLL and cationic lipids on endosom-
al release. The improvement in transfection efficiency us-
ing sPLLs was also confirmed in vivo in a porcine reste-
nosis model. Thus, lipopolyplexes containing sPLLs with 
up to 30 lysine residues, and particularly those contain-
ing L18, may be promising agents for improved liposome-
mediated GT into vascular cells. 
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